ontazolast

inhibits arachidonate release that blocks leukotriene B4 and platelet-activating factor biosynthesis in human neutrophils

Also Known As:

BIRM 270; BIRM-270; N-(2-cyclohexyl-1-(2-pyridinyl)ethyl)-5-methyl-2-benzoxazolamine; 2-Benzoxazolamine, N-(2-cyclohexyl-1-(2-pyridinyl)ethyl)-5-methyl-, (S)-

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzoxazoles: 68
      - ontazolast: 1

Experts

1.	Brady, J T: 1 article (11/2000)
2.	Hamlin, R L: 1 article (11/2000)
3.	Nakayama, T: 1 article (11/2000)
4.	Stoll, R E: 1 article (11/2000)

Related Diseases

1.	Torsades de Pointes (Torsade de Pointes) 11/01/2000 - "To determine whether QT interval is prolonged or sudden death is caused by ventricular fibrillation resulting from torsades de pointes and to identify hemodynamic effects of ontazolast. "
2.	Ventricular Fibrillation 11/01/2000 - "To determine whether QT interval is prolonged or sudden death is caused by ventricular fibrillation resulting from torsades de pointes and to identify hemodynamic effects of ontazolast. "
3.	Sudden Death 11/01/2000 - "To determine whether QT interval is prolonged or sudden death is caused by ventricular fibrillation resulting from torsades de pointes and to identify hemodynamic effects of ontazolast. "
4.	Body Weight (Weight, Body) 11/01/2000 - "Physiologic variables were measured for 2 hours in conscious dogs given ontazolast (0, 1, or 3 mg/kg of body weight, IV) and for 1 hour in anesthetized dogs given cumulative doses of ontazolast (0, 1, 3, 6, or 8 mg/kg, IV). "